Literature DB >> 20202745

Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo.

Hua Yang1, Fuxia Xiong, Xuanhui Wei, Yu Yang, Michael A McNutt, Rouli Zhou.   

Abstract

LAPTM4B-35, encoded by Lysosomal protein transmembrane 4 beta (LAPTM4B) is over-expressed in more than 71% of hepatocellular carcinomas (HCCs) and associated with prognosis of the patients. But the exact role and molecular mechanism in HCC have not been determined. In this study, we explored the effects and mechanisms of LAPTM4B-35 on tumor growth and metastasis in vitro and in vivo by overexpression and depletion of LAPTM4B in HCC HepG2 and Bel7402 cells. These findings suggest that overexpression of LAPTM4B-35 plays a critical role in the growth and metastasis of HCC, and LAPTM4B-35 may therefore be a therapeutic target for HCC. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202745     DOI: 10.1016/j.canlet.2010.02.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  30 in total

1.  Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients.

Authors:  Hua Yang; Guojun Zhai; Xiaoxu Ji; Fuxia Xiong; Jing Su; Michael A McNutt
Journal:  Med Oncol       Date:  2012-12       Impact factor: 3.064

2.  LAPTM4B is a PtdIns(4,5)P2 effector that regulates EGFR signaling, lysosomal sorting, and degradation.

Authors:  Xiaojun Tan; Yue Sun; Narendra Thapa; Yihan Liao; Andrew C Hedman; Richard A Anderson
Journal:  EMBO J       Date:  2015-01-14       Impact factor: 11.598

3.  LAPTM4B-35 is a novel prognostic factor for glioblastoma.

Authors:  Xiaoshud Dong; Kaoru Tamura; Daisuke Kobayashi; Noboru Ando; Kazutaka Sumita; Taketoshi Maehara
Journal:  J Neurooncol       Date:  2017-01-18       Impact factor: 4.130

4.  Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells.

Authors:  Yang Li; Qing Zhang; Ruiyang Tian; Qi Wang; Jean J Zhao; J Dirk Iglehart; Zhigang Charles Wang; Andrea L Richardson
Journal:  Cancer Res       Date:  2011-10-28       Impact factor: 12.701

5.  Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells.

Authors:  Caroline Huygens; Stéphanie Liénart; Olivier Dedobbeleer; Julie Stockis; Emilie Gauthy; Pierre G Coulie; Sophie Lucas
Journal:  J Biol Chem       Date:  2015-06-30       Impact factor: 5.157

6.  A kinase-independent role for EGF receptor in autophagy initiation.

Authors:  Xiaojun Tan; Narendra Thapa; Yue Sun; Richard A Anderson
Journal:  Cell       Date:  2015-01-15       Impact factor: 41.582

7.  Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer.

Authors:  Han Tang; Hui Tian; Weiming Yue; Lin Li; Shuhai Li; Cun Gao; Libo Si; Lei Qi; Ming Lu
Journal:  Med Oncol       Date:  2014-05-11       Impact factor: 3.064

8.  Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer.

Authors:  Man Qiao; Guohua Hu
Journal:  Tumour Biol       Date:  2015-04-25

9.  LAPTM4B facilitates late endosomal ceramide export to control cell death pathways.

Authors:  Tomas Blom; Shiqian Li; Andrea Dichlberger; Nils Bäck; Young Ah Kim; Ursula Loizides-Mangold; Howard Riezman; Robert Bittman; Elina Ikonen
Journal:  Nat Chem Biol       Date:  2015-08-17       Impact factor: 15.040

10.  Targeting a novel cancer-driving protein (LAPTM4B-35) by a small molecule (ETS) to inhibit cancer growth and metastasis.

Authors:  Maojin Li; Rouli Zhou; Yi Shan; Li Li; Lin Wang; Gang Liu
Journal:  Oncotarget       Date:  2016-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.